Loomis Sayles & Co. L P Trims Stake in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Loomis Sayles & Co. L P trimmed its position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 16.6% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 280,166 shares of the medical equipment provider's stock after selling 55,862 shares during the period. Loomis Sayles & Co. L P owned about 0.40% of Lantheus worth $30,748,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Moloney Securities Asset Management LLC purchased a new stake in shares of Lantheus in the 3rd quarter valued at approximately $1,066,000. Hancock Whitney Corp lifted its holdings in Lantheus by 265.6% during the 1st quarter. Hancock Whitney Corp now owns 20,151 shares of the medical equipment provider's stock worth $1,254,000 after buying an additional 14,639 shares during the last quarter. Wealth Enhancement Advisory Services LLC purchased a new stake in Lantheus during the 2nd quarter worth about $290,000. Van ECK Associates Corp boosted its position in shares of Lantheus by 58.6% during the 3rd quarter. Van ECK Associates Corp now owns 58,472 shares of the medical equipment provider's stock worth $6,469,000 after acquiring an additional 21,604 shares in the last quarter. Finally, Swedbank AB increased its holdings in shares of Lantheus by 21.1% in the 3rd quarter. Swedbank AB now owns 722,243 shares of the medical equipment provider's stock valued at $79,266,000 after acquiring an additional 125,843 shares during the last quarter. Institutional investors and hedge funds own 99.06% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on LNTH shares. Redburn Atlantic assumed coverage on Lantheus in a report on Tuesday, September 3rd. They issued a "buy" rating and a $175.00 price target for the company. StockNews.com cut shares of Lantheus from a "buy" rating to a "hold" rating in a report on Thursday, November 21st. JMP Securities reduced their price target on shares of Lantheus from $125.00 to $112.00 and set a "market outperform" rating for the company in a research report on Thursday, November 7th. Finally, Truist Financial restated a "buy" rating and issued a $120.00 price objective (down previously from $135.00) on shares of Lantheus in a research note on Friday, November 8th. Two analysts have rated the stock with a hold rating and eight have given a buy rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $122.50.

Lantheus Price Performance

Shares of NASDAQ:LNTH traded down $1.43 on Tuesday, reaching $89.53. The company's stock had a trading volume of 1,246,380 shares, compared to its average volume of 1,023,089. Lantheus Holdings, Inc. has a 52-week low of $50.20 and a 52-week high of $126.89. The stock has a market capitalization of $6.22 billion, a P/E ratio of 14.94 and a beta of 0.51. The stock's 50-day moving average is $102.80 and its two-hundred day moving average is $97.04.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.